The DOI matches its Crossref record.
Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development
Abstract
Actin was first identified in non-muscle cells only about three decades ago, and at about the same time, it was found that actin filaments were disrupted in the malignant transformed cells. The actin network is a rather complex, yet important structural and functional system of all eukaryotic cells. Actin filaments provide the basic infrastructure for maintaining cell morphology and functions such as adhesion, motility, exocytosis, endocytosis, and cell division. Growing evidence from this laboratory and others shows that alterations of actin polymerization, or actin remodeling, plays a pivotal role in regulating the morphologic and phenotypic events of a malignant cell. Actin remodeling is the result of activation of oncogenic actin signaling pathways (e.g., Ras and Src), or inactivation of several important actin-binding proteins that have tumor suppressor functions (e.g., gelsolin). Distinctive protein expression patterns of some of these genes in cancer and progressive carcinogenic processes have been observed. It has become evident that actin dynamics are regulated by a complex interplay of the small GTPase proteins of Ras superfamily Rac, Rho, and Cdc42, and efforts to develop specific inhibitors for these small G proteins as anticancer drug are underway. In this review we will discuss how actin remodeling is altered in the malignant transformation process, the functional significance of actin alteration in association with malignant phenotypes, and the approaches of targeting actin remodeling for chemopreventive and chemotherapeutic drug development. Approaches including using nature products directly modulating actin polymerization, using inhibitors of actin pathway small G proteins, and using gene-augmentation for actin binding proteins will be discussed. In addition, the concept of using F/G-actin ratio as a surrogate marker for actin-pathway based therapy will also be introduced.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nanomechanical analysis of cells from cancer patients
Cross, S. E., Jin, Y.-S., Rao, J., & Gimzewski, J. K. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.388 · Cited by 1,908
Self-citationCell Stiffness Is a Biomarker of the Metastatic Potential of Ovarian Cancer Cells
Xu, W., Mezencev, R., Kim, B., Wang, L., McDonald, J., & Sulchek, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046609 · Cited by 760
Lefranc, F., Brotchi, J., & Kiss, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.089 · Cited by 526
Mechanisms of cancer cell invasion
Sahai, E. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.002 · Cited by 515
AFM-based analysis of human metastatic cancer cells
Cross, S. E., Jin, Y.-S., Tondre, J., Wong, R., Rao, J., & Gimzewski, J. K. (2008) · Nanotechnology · doi:10.1088/0957-4484/19/38/384003 · Cited by 418
Self-citation
Metadata
- Authors
- Rao, J., & Li, N.
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 4
- Pages
- 345-354
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2016062730
- Cited by
- 183
- References
- 0
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development. https://app.cochat.ai/papers/10.2174/1568009043332998
- The paper
- Rao, J., & Li, N. (2004). Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development. Current Cancer Drug Targets. https://doi.org/10.2174/1568009043332998
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.